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Direct diagnosis of mucous membrane pemphigoid 
(MMP) is not easy. Circulating autoantibodies targeting 
bullous pemphigoid antigens of 180 kDa and 230 kDa 
(BP180 and BP230), α6β4 integrin, laminin 332 and type 
VII collagen (Col VII) are not always present. The aims 
of this study were to characterize the humoral immune 
response of a cohort of Italian patients with MMP, its 
association with clinical involvement and severity, and 
to design an algorithm for efficient serological diagnosis. 
Seventy-eight MMP sera were studied retrospectively by 
indirect immunofluorescence on salt-split skin, enzyme-
linked immunosorbent assay (ELISA) and immuno-
blotting. Indirect immunofluorescence on salt-split skin 
resulted in the most sensitive approach for diagnosis of 
MMP. BP180 was the major autoantigen in MMP pa-
tients with oral and cutaneous involvement. Significant 
associations were found between BP180 reactivity and 
oral and cutaneous localization of the lesions (p = 0.006), 
and between Col VII positivity and Setterfield severity 
score (p = 0.020). Key words: autoantibody; mucous mem-
brane pemphigoid; diagnosis.
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Mucous membrane pemphigoid (MMP) comprises a hete-
rogeneous group of autoimmune sub-epithelial bullous di-
seases, predominantly affecting mucous membranes with 
or without skin involvement, leading to scarring phenotype 
(1, 2). MMP also includes those blistering diseases, such 
as mucous membrane-dominant epidermolysis bullosa ac-
quisita and linear IgA bullous dermatosis, with preferential 
mucous membrane involvement (1). MMP is characterized 
by deposits of immunoglobulin G (IgG) and/or IgA and/
or complement fragments at the dermal-epidermal and/or 
chorio-epithelial basement membrane zone (BMZ) and, 
at least in some patients, circulating IgG and/or IgA auto-
antibodies targeting several BMZ components, including 
the bullous pemphigoid antigens of 180 kDa (BP180) and 
230 kDa (BP230) (3–7), α6β4 integrin (8, 9), laminin 332 
(10, 11) and type VII collagen (Col VII) (1).
BP180 and BP230 are components of the junctional 
adhesion complex called hemidesmosome. BP230 is a 
cytoplasmic protein implicated in the organization of the 
keratin filament network and BP180 is a transmembrane 
protein that, by interaction with α6β4, contributes to the 
assembly and stabilization of hemidesmosomes (12, 
13). In addition, α6β4 integrin mediates cell adhesion to 
extracellular matrix, and laminin 332 and Col VII play 
an important role in the maintenance of epithelial cell 
anchorage to the underlying connective tissue (14–16). 
In ex vivo and in vivo models it has been demonstrated 
that autoantibodies against laminin 332 and β4 integrin 
have a role in the pathogenesis of MMP (9, 17). 
Diagnosis of MMP is made through clinical findings, 
assessment of sub-epithelial blister by histopathology, 
detection of linear deposition of autoantibodies at the 
BMZ by direct immunofluorescence (DIF) and binding 
to the roof and/or floor of the blister of salt-split skin 
by indirect immunofluorescence (IIF-SSS). Commer-
cially available ELISAs, based on proteins involved in 
dermo-epidermal or chorio-epithelial adhesion, are also 
usually employed for serological diagnosis of MMP. In 
particular, the major targets of autoantibodies are BP180 
(both NC16A and C-terminal domain) and laminin 332, 
and diagnoses of anti-BP180 and anti-laminin 332 type 
MMP, respectively, are frequently made. 
The present retrospective study characterized the 
humoral immune response of 78 Italian patients with 
MMP using standard approaches, such as IIF-SSS and 
commercial ELISAs, to design an algorithm for efficient 
serological diagnosis.
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METHODS
Patients
Seventy-eight sera, collected from 2013 to 2014, were studied 
retrospectively. The sera were collected from 54 women and 
24 men (mean age 74 years) with MMP observed in different 
Italian clinical centres (Turin, Genoa, Ravenna, Milan and 
Florence). In accordance with the international consensus on 
MMP, patients with predominantly mucosal membrane disease 
were classified as MMP even though they only have autoan-
tibodies to Col VII (1). From a clinical point of view, the 78 
patients presented different clinical involvement: oral (OR), 
ocular (OC), skin Brunsting-Perry (BP) variant, naso-pharynx 
(NP) and genital (G). In particular, 39 patients (#1–39) were 
classified as OR-MMP, 10 (#40–49) as OC-MMP, 5 (#50–54) as 
BP-MMP variant, and 24 (#55–78) presented a mixed form with 
both cutaneous and mucous involvement. Out of these patients 
with mixed form, 5 (#55–59) had OR/OC-MMP, 3 (#60–62) 
OR/BP-MMP, 3 (#63–65) OR/OC/NP-MMP, 3 (#66–68) OC/
BP-MMP, 2 (#69–70) OR/NP-MMP, 1 (#71) OR/G-MMP, 1 
(#72) OC/NP-MMP, 1 (#73) OR/NP/BP-MMP, 1 (#74) OR/
BP/G-MMP, 1 (#75) OR/OC/BP-MMP, 1 (#76) OR/NP/G-
MMP, 1 (#77) OC/BP/NP-MMP and 1 (#78) OC/BP/G-MMP 
(Table SI1). According to Setterfield score, a reproducible 
system for scoring clinical sites (skin, ocular, oral gingiva, 
oral non-gingival sites, naso/pharynx, larynx, oesophagus, and 
genital), which would minimize observer variability, and allow 
accurate assessment of both disease severity and response to 
therapeutic intervention (18), our patients were allocated an 
initial clinical score based on the sum of individual site severity 
scores at presentation. The disease severity of our patients was 
then classified into 4 classes: I (score 0–4), II (score 5–9), III 
(score 10–14) and IV (score ≥ 15). The clinical diagnosis was 
confirmed by histology and by the presence of IgG/IgA at the 
BMZ by DIF. The sera of 10 healthy individuals were used as 
controls for the laminin 332 detection assay.
Indirect immunofluorescence 
IIF was performed on monkey oesophagus (MO), utilizing com-
mercial slides (BioSystems S.A. Barcelona, Spain). IIF-SSS 
was performed utilizing a commercial kit (Immco Diagnostics, 
NY, USA). All sera were diluted to 1:20 in phosphate-buffered 
saline (PBS). The slides were incubated with the diluted sera 
for 30 min. After washing in PBS, the slides were covered 
with fluorescein isothiocyanate-conjugated goat anti-human 
IgG or IgA (Kallestad Diagnostic, Chaska, MN, USA) for 30 
min. Following a further PBS washing, the slides were moun-
ted in buffered glycerine and examined under a fluorescence 
microscope (Leitz, Wetzlar, Germany). IIF titre was considered 
positive when higher than 1:40.
Enzyme-linked immunosorbent assay
ELISA was performed using commercial kits (MBL, Naka-
Ku Nagoya, Japan) consisting of microwells coated with 
recombinant proteins encompassing BP230, BP180 and Col 
VII. According to the manufacturer’s recommendations, the 
cut-off value for both BP230 and BP180 was 9.0 (U/ml), and 
for Col VII the cut-off value was 6.0 (U/ml). To compare the 
results from different plates, the test sample optical densities 
(OD) were adjusted according to positive and negative control 
samples supplied in each kit. The final results were expres-
sed as a percentage according to the following calculation: 
OD sample – OD negative control/OD positive control – OD 
negative control × 100. 
Laminin 332 affinity purification
Squamous carcinoma cells (SCC) 25 (CCL 25; American Type 
Culture Collection) were grown in 50% Ham’s F-12 (Life Tech-
nologies, Milan, Italy) and 50% Dulbecco’s-modified Eagle’s 
medium (Life Technologies), supplemented with 10% foetal 
bovine serum (FBS) (GE Healthcare Bio-Sciences, Pittsburgh, 
PA, USA), 4 mM glutamine (Life Technologies), hydrocortisone 
(0.4 µg/ml) (Merck, Milan, Italy), 50 U/ml penicillin, and 50 
µg/ml streptomycin (Life Technologies). The culture medium, 
harvested from confluent SCC25 culture after 24 h in medium 
without serum with 0.1% bovine serum albumin (BSA), was 
centrifuged to remove cells and filtered. The medium was con-
centrated 20-fold by centrifugation with Amicon Ultra (cut-off 
10,000 Da) (Millipore, Billerica, MA, USA), dialysed against 
PBS, passed over bovine gelatin coupled to Sepharose™ 4B 
(GE Healthcare) to remove fibronectin, and stored at 4°C after 
addition of protease inhibitors (5 mM EDTA, complete) (Roche 
Diagnostics, Indianapolis, IN, USA). Subsequently, laminin 
332 was purified by passage over K140 sepharose (mouse 
MoAb to the laminin 332 β3 chain; gift from R. Burgeson, 
Cutaneous Biology Research Center, Charlestown, MA, USA) 
(19). Laminin 332 was eluted from K140 sepharose using 100 
mM glycine pH 2.8. The fractions containing laminin 332 
were neutralized by adding 1 M Tris-HCl, pH 9, pooled and 
dialysed against PBS.
Immunoblotting
SDS-polyacrylamide gel electrophoresis was performed using 
a 6% polyacrylamide gel loaded with 5 µg purified laminin 
332 per lane, in reducing conditions. Immunoreactivity was 
detected, after transfer to polyvinylidene difluoride membrane 
(Immobilon-P; Millipore), by incubation with a 1:100 dilution of 
patient and control sera and monoclonal antibodies to laminin 332 
K140 (anti-β3), BM165 (anti-α3) (20), U46 (anti-γ2 polyclonal 
antibody produced in our laboratory), followed by incubation 
with alkaline phosphatase-labelled secondary antibodies. 
Statistical analysis
Associations between disease severity and IIF microscopy or 
antigen reactivity, expressed as dichotomous variable (absent/
present) were assessed using Mann-Whitney (for category 
variables with 2 categories). Prevalence differences of IIF mi-
croscopy or antigen reactivity on patients with different disease 
localization (oral, ocular, skin, multiple site) were assessed with 
χ2 test calculated on contingency tables. Fisher’s exact test was 
used when expected counts were less than 5. All analyses were 
performed using Stata statistical package (2005. Stata Statistical 
Software: Release 9. College Station, TX, USA: StataCorp LP).
RESULTS
Patients
A total of 78 MMP sera from different Italian clinical 
centres were retrospectively studied, including 39 
(50%) OR-MMP, 10 (12.8%) OC-MMP, 5 (6.4%) BP-
MMP and 24 (30.8%), presenting a mixed form with 
both cutaneous and mucous involvement. Fifty-seven 
out of 78 (73%) patients with MMP presented oral 1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2311
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involvement (Table SI1), which is the most affected 
mucosal site, as previously reported (21). 
Indirect immunofluorescence results
When tested by IIF, only 2 sera of the 78 MMP pa-
tients (2.6%) were IgG-positive using MO (IgG) as 
a substrate. In contrast, when analysed by IIF-SSS, 
IgG and/or IgA positivity was found in 45 MMP sera 
out of 78 (58%), confirming the higher sensitivity of 
this technique in comparison with IIF on MO (Table 
SI1). In particular, as for the 37 IgG-positive patients, 
22 (59.5%) patients’ sera had a double positivity pat-
tern (roof and floor), 11 (29.7%) had positivity only 
at the roof and 4 (10.8%) only at the floor. As for the 
23 IgA-positive patients, 8 (34.8%) patients’ sera had 
a double positivity pattern (roof and floor), 8 (34.8%) 
had positivity only at the roof, and 7 (30.4%) patients’ 
only at the floor (Table SI1). As regards the relationship 
between clinical variant and the IIF-SSS reactivity 
pattern, no statistical significant result was found. In 
addition, no significant association was found between 
IIF-SSS reactivity and disease severity score.
IgG reactivity profile 
The MMP sera reactivity profile was investigated using 
3 commercially available ELISA kits for detection of 
autoantibodies targeting BP180, BP230 and Col VII 
and an immunoblotting (IB) analysis based on affinity 
purified laminin 332. BP180 ELISA was positive in 26 
patients (33%), BP230 ELISA was positive in 9 patients 
(11.5%) and Col VII ELISA in 3 patients (3.8%) (Table 
SI1) (Fig. 1a). IgG reactivity to laminin 332 on IB was 
found in 9 out of 78 patients’ sera (11.5%) and in no 
control sera (Fig. 1b). All laminin 332-positive sera 
reacted against the α3 chain, 3 out of 9 bound to γ2 
and 1 out of 9 to β3 (Fig. 1b and data not shown). Of 
note, no relationship between laminin 332 positivity 
and associated internal cancer was found (data not 
shown). Even if bound by a relatively low number of 
sera, BP180 represents the most recognized antigen in 
the present cohort of patients with MMP.
Correlation between target antigen, clinical variant 
and disease severity
As regards the relationship between target antigen, 
clinical variant and Setterfield score, among the 26 
BP180-positive patients, 17 had OR-MMP variant, 
1 had an OC-MMP variant, 4 had BP-MMP type and 
4 had a mixed variant (OR/BP-MMP; OR/NP-MMP; 
OR/G-MMP; OR/NP/BP-MMP), showing a significant 
association between BP180 reactivity and oral and 
cutaneous localization of the lesions (p = 0.006) (Table 
SI1 and Fig. 2). Of note, BP180 reactivity presented 
a significant inverse association with disease severity 
Fig. 1. Mucous membrane pemphigoid (MMP) sera reactivity profile. (A) 
BP180 enzyme-linked immunoassay (ELISA) was positive in 26 patients 
(33%); 9 patients (11.5%) were positive by BP230 ELISA and 3 (3.8%) by 
collagen VII ELISA. Immunoglobulin G (IgG) reactivity to purified laminin 
332 by immunoblotting analysis was found in 9 out of 78 patients’ sera 
(11.5%). (B) Immunoblotting of some representative positive (#40, #76, 
#24 in lanes 1, 2, 4, respectively), negative patient sera (#7 in lane 3) and 
normal sera (lanes 5, 6) against affinity purified laminin 332. Monoclonal 
antibodies K140 (lane 7), BM165 and U46 (lane 8) bind β3 and α3 and 
γ2 chain, respectively.
Fig. 2. Relationship between target antigen and mucous membrane 
pemphigoid (MMP) clinical variant. Out of 26 BP180-positive patients 17 
had OR-MMP variant, 1 had an OC-MMP variant, 4 had BP-MMP type 
and 4 a mixed variant (OR/BP-MMP; OR/NP-MMP; OR/G-MMP; OR/
NP/BP-MMP). Out of 9 BP230-positive patients, 5 had OR-MMP, 1 an 
OC-MMP, 1 had BP-MMP type and 2 a mixed form (OR/BP-MMP; OR/
NP-MMP). Of 9 laminin-332-positive patients, 4 had an OR-MMP, 1 had 
an OC-MMP and 4 a mixed form (2 OR/OC-MMP; 1 OR/NP/G-MMP; 1 
OC/BP/NP-MMP). All 3 collagen VII-positive patients presented a mixed 
form (OR/NP-MMP; OR/NP/BP-MMP; OC/BP/G-MMP).
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score (p = 0.025) (data not shown). On the other hand, 
all 3 Col VII-positive patients presented a mixed form 
(OR/NP; OR/NP/BP; OC/BP/G) with the involvement 
of multiple mucosal sites, also showing a significant 
association with severity score (p = 0.020) (data not 
shown). Finally, no significant association was found 
between disease severity score, clinical variant and 
reactivity against BP230 or laminin 332. 
DISCUSSION
In patients with a severe form of MMP, timely di-
agnosis and appropriate treatment are essential. The 
laboratory diagnosis of MMP relies mainly on the 
detection of tissue-bound autoantibodies by DIF and 
the demonstration of serum autoantibodies binding to 
the BMZ component using IIF-SSS and/or antigen-
based ELISAs. Chan and co-workers (1), in the first 
international consensus on MMP, assert that MMP also 
includes mucous membrane-dominant epidermolysis 
bullosa acquisita and linear IgA bullous dermatosis 
with preferential mucous membrane involvement. The 
consensus underlines the supremacy of the clinical 
picture (predominant mucosal involvement) over the 
immunological features, also considering “the principle 
that MMP can no longer be defined by a specific target 
antigen because multiple antigens have been identified 
by the autoantibodies of this group of patients” (1).
The present study: (i) characterized the autoantibody 
profile of 78 Italian patients with MMP; (ii) confirmed 
that BP180 is the major autoantigen of MMP patients 
with oral and cutaneous involvement; (iii) and identified 
BP180 reactivity as an inverse marker of disease severity.
To our knowledge, this is the largest Italian cohort of 
MMP patients that has been investigated clinically and 
serologically. To assess disease severity, the Setterfield 
score was employed, as it was considered more suitable 
to our purposes than other existing MMP outcome me-
thods, particularly considering the predominance of oral 
involvement in our cohort. More recently, another sco-
ring system has been proposed, but it was not available 
at the time of completion of the present study (22). We 
showed that 45 out of 78 MMPs (58%) had IgG and/or 
IgA that reacted with epidermal and/or dermal side of 
salt-split skin by IIF-SSS, confirming that this technique 
is the most sensitive approach to detect autoantibodies in 
patients with MMP. In contrast, standard MO IIF should 
probably be abandoned for assessing patients with MMP. 
In contrast with a previous study, in our cohort the 
presence of both circulating IgG and IgA anti-BMZ 
antibodies by IIF was not associated with more severe 
disease (p = 0.563, data not shown) (18), suggesting that 
IIF-SSS results are not helpful to predict the clinical 
severity of MMP. 
Longitudinal studies of a cohort of patients with po-
sitivity against laminin 332 suggested that this form is 
associated with an increased relative risk of solid can-
cers (23, 24). In contrast, a recent study did not confirm 
these results, showing that the presence of solid tumours 
and lymphomas was not higher in patients with anti-
laminin 332 autoantibodies (11). In the present study 
no significant correlation was found between laminin 
332 reactivity and the proportion of patients with an 
associated internal cancer. The reported frequency of 
reactivity to laminin 332 in patients with MMP ranged 
from 18% to 30% (11, 25–29). In our cohort of MMP 
patients, 9 of 78 (11, 5%) reacted to laminin 332, and 
4 of 9 were negative by IIF-SSS, demonstrating that, 
in these MMP patients, immunoblotting on affinity-
purified laminin 332 is more sensitive than IIF-SSS. 
These data are in line with a recent study showing that 
almost half of MMP sera that were found to be positive 
for anti-laminin 332 antibodies by ELISA were negative 
by IIF-SSS (11). Moreover, data from our study and 
from the study by Bernard et al. (11) clearly suggest 
that, despite IIF-SSS being the most sensitive first-line 
serological test for detecting circulating autoantibodies 
in MMP, it is probably less helpful than originally 
thought for predicting laminin 332 positivity. All 3 
chains of laminin 332 have been shown to be bound 
by MMP sera; however, according with previously re-
ported data the α3 subunit is the most-recognized chain 
of laminin 332 in our cohort of patients (10). Of note, 
there was no significant relationship between laminin 
332 positivity, disease severity and clinical variant.
Since the interaction between laminin 332 and BP180 
has a crucial role in dermal-epidermal and chorio-
epidermal adhesion (15, 16, 30, 31), autoantibodies 
against laminin 332 and/or BP180 may contribute to the 
pathogenesis of MMP by interfering with this adhesion 
complex. In this context, we have shown that 33% of 
patients with MMP possessed circulating autoantibo-
dies against the BP180 molecule (specifically, its im-
munodominant region NC16A used as antigen in the 
commercial ELISA), indicating a role of this protein 
in the pathogenesis of MMP. Interestingly, Oyama and 
co-workers have shown a higher reactivity (75% of 
MMP sera) against the entire BP180 antigen, further 
confirming that regions other than NC16A may be re-
cognized by MMP autoantibodies (5–7). In particular, 
a frequent reactivity of MMP patients’ autoantibodies 
against the C-terminal portion of BP180 has been 
reported, the reason for which is unknown (3, 7). The 
observation that patients with oral pemphigoid without 
scarring phenotype frequently react to the C-terminal 
portion of BP180 challenged the possible relation of 
this reactivity with the scarring phenotype (7).
The significant correlation between BP180 reactivity 
and exclusive cutaneous and/or oral involvement is in 
line with previous studies in which reactivity against 
NC16A was mainly found in a cohort of MMP patients 
with exclusively oral involvement and MMP patients 
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with skin involvement (3, 7). In this context, the inverse 
correlation between BP180 reactivity and disease seve-
rity might provide a predictive marker relevant for the 
management of the patients, and challenge the hypo-
thesis about the possible role of BP180 autoantibodies 
in the pathogenesis of MMP.
Antigens targeted by IgG autoantibodies in MMP 
included BP230 (6, 7, 11). In our cohort, 11.5% of pa-
tients with MMP recognized BP230 and, interestingly, 
almost in all cases reacted also to BP180. In a previous 
study on patients with BP, an autoimmune bullous 
disease characterized by a predominantly cutaneous 
involvement, Di Zenzo and co-workers (32) have de-
monstrated that IgG autoantibodies first targeted the 
BP180 ectodomain and only subsequently recognized 
BP230. In the light of these findings it could be postu-
lated that in these patients with MMP an intermolecular 
epitope spreading phenomenon occurred. In particular, 
an initial immune response against the extracellular im-
munodominant epitope of BP180 could induce tissue 
damage that eventually leads to disease progression 
associated with further IgG recognition of an intracel-
lular antigen, BP230. In this context, even if never 
reported for patients with MMP, the detected anti-Col 
VII reactivity could also be due to an epitope spreading 
phenomenon, at least, in 2 of 3 Col VII-positive pa-
tients, which also targeted BP180 and BP230 (33, 34). 
The remaining case with exclusive reactivity against 
Col VII represents an epidermolysis bullosa acquisita 
with predominantly mucosal involvement (skin, genital 
and ocular) and scar formation. In these patients, the 
Col VII reactivity appears to be significantly related to 
disease severity, showing a role of such autoantibodies 
in the disease pathogenesis. Interestingly, a number of 
MMP sera (29%), higher than previously reported in a 
limited cohort of Japanese patients with MMP (13%) 
(35), showed IgG and/or IgA that reacted with both 
epidermal and dermal side of salt-split skin by IIF. This 
finding could suggest that Italian patients with MMP 
may have autoantibodies to multiple antigens residing in 
both epidermal and dermal sides. To confirm a possible 
racial difference between Japanese and Italian patients 
further studies are needed on larger cohorts. 
One of the major limitations of our study was that we 
employed only the most well-established diagnostic pro-
cedure, such as ELISAs based on BP180, BP230 and Col 
VII and immunoblotting on affinity purified laminin 332. 
However, other antigens (α6, β4) have been reported to 
be targeted by MMP autoantibodies (6, 8, 9) and should 
be investigated in further studies. In accordance with 
Hayakawa et al. (35) suggesting that a combination of im-
munological testing for circulating autoantibodies is use-
ful for the diagnosis of MMP, and in light of our findings, 
we can draw an algorithm for the efficient serological 
diagnosis of MMP. In particular, in patients with positive 
DIF we suggest performing IIF-SSS that could provide an 
IgA- and/or IgG-positive result in 58% of cases. Of note, 
in the presence of a typical clinical picture and negative 
DIF also after a second biopsy, further immunological 
studies may be necessary and could represent surrogate 
markers for diagnosis (36, 37). Secondly, the use of 
commercially available ELISAs, that are simple, rapid, 
give quantitative results and require a small amount of 
serum, could be important to detect autoantibody reactiv-
ity in IIF-negative sera or could also have a confirmatory 
role. Specifically, the most efficient hierarchy process 
involves performing a BP180 ELISA, which is positive 
in 33% of patients, and IB/ELISA on integrin α6, β4 
and C-terminal domain of BP180 antigen, which has 
been reported positive especially in MMP patients with 
oral, ocular involvement and with scarring phenotype, 
respectively (3, 8, 9). Thereafter, IB on laminin 332 
that yields positive in 11.5% of patients or laminin 332 
ELISA, even if not available in most laboratories, should 
be performed. MMP sera that are negative for IIF, as well 
as for BP180, α6β4 integrin and laminin 332 ELISA, 
should be tested with Col VII ELISA (which is positive 
Fig. 3. Mucous membrane pemphigoid serological algorithm.
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in 4% of patients). BP230 ELISA, which was found to 
be positive in 9 sera in our study, representing the sole 
positive test in only one of them, should be performed 
as the final diagnostic assay in doubtful cases that have 
negative results in the other tests. Since the combined 
sensitivity of these assays is 77% (without considering 
the BP180 C-terminal domain and α6β4 reactivity not 
analysed in the present study), the remaining patients who 
were not positive in any diagnostic procedure used (i.e. 
in the present study 18 out of the 78 patients with MMP) 
could be analysed by immunoblot on epithelial extracts 
to detect other possible target antigens (Fig. 3). Further 
studies are needed to evaluate the possible advantages of 
the use of commercially available diagnostic procedures 
based on multiple antigens (38).
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